Squamous cell carcinoma arising from mature cystic teratoma of the ovary: A challenging question for gynecologic oncologists

Crit Rev Oncol Hematol. 2019 Jan:133:92-98. doi: 10.1016/j.critrevonc.2018.10.005. Epub 2018 Nov 2.

Abstract

Mature cystic teratomas of the ovary have an incidence of 1.2-14.2 cases per 100.000 people per year. Malignant transformation occurs in approximately 2% of the cases, and usually consists of squamous cell carcinoma. The preoperative detection is difficult and the diagnostic accuracy of ultrasound, magnetic resonance imaging, and computed tomography is debated. The diagnosis is frequently made in the operating room or on final histological examination. Standard treatment consists of bilateral salpingo-oophorectomy, total hysterectomy and comprehensive surgical staging in early disease and optimal cytoreductive surgery in advanced disease. Paclitaxel/carboplatin- based chemotherapy is the most used adjuvant treatment, whereas more aggressive regimens can be adopted in patients with high tumor burden or recurrent disease. The efficacy of radiotherapy is still unproven. The prognosis is poor when the tumor has spread beyond the ovary. There are few information to provide commonly accepted guidelines for this malignancy.

Publication types

  • Review

MeSH terms

  • Carcinoma, Squamous Cell / diagnosis
  • Carcinoma, Squamous Cell / pathology*
  • Carcinoma, Squamous Cell / therapy
  • Cell Transformation, Neoplastic / pathology
  • Diagnosis, Differential
  • Diagnostic Techniques, Obstetrical and Gynecological*
  • Disease Progression
  • Female
  • Humans
  • Medical Oncology / methods
  • Neoplasm Staging
  • Ovarian Cysts / diagnosis*
  • Ovarian Cysts / pathology*
  • Ovarian Cysts / therapy
  • Ovarian Neoplasms / diagnosis
  • Ovarian Neoplasms / pathology*
  • Ovarian Neoplasms / therapy
  • Teratoma / diagnosis
  • Teratoma / pathology*
  • Teratoma / therapy